L
Lyra Therapeutics
Lyra Therapeutics is a clinical-stage company developing medicines
About Lyra Therapeutics
Lyra Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. The company leverages its expertise in materials science, drug development, and formulation to create proprietary technology designed to deliver medicines directly, precisely, and consistently to the affected tissue for sustained periods with a single administration. Lyra Therapeutics' product candidates, LYR-210 and LYR-220, are bioabsorbable nasal implants intended to deliver up to six months of continuous mometasone furoate drug therapy through a brief, in-office procedure. The company's business model revolves around the development and commercialization of these specialized treatments, targeting patients suffering from CRS who cycle through various treatment options seeking lasting relief. Lyra Therapeutics operates in the biotechnology and pharmaceutical markets, primarily serving healthcare providers and patients dealing with CRS. The company generates revenue through the development, approval, and eventual sale of its proprietary drug delivery systems.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Watertown, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
News
Open roles
Lyra Therapeutics in the Watertown ecosystem
The Lyra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Perceptive Advisors
Polaris Partners
Intersouth Partners
RA Capital Management
ArrowMark Partners
Series B and later7 investors entered at this stage
Clinton Capital Partners- NMNantahala Capital Management
- VPVenrock Healthcare Capital Partners
North Bridge Venture Partners
Citadel
Samsara BioCapital
Woodline Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lyra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lyra Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

